Evaluation of the Use of SGLT2 Inhibitor in the Symptomatic Improvement of Patients with Chagas Cardiomyopathy

Chagas cardiomyopathy (CC) remains a serious disease with a poor prognosis in Latin America, and its treatment is based on the use of drugs commonly prescribed for heart failure (HF). Sodium glucose cotransporter-2 inhibitors (SGTL2i) improved cardiovascular mortality and HF hospitalization in several trials. As a result of growing body evidence in HF from different etiologies, it is reasonable to consider its potential benefits in CC. This study describes the impact on quality of life (QoL), using the New York Heart Association (NYHA) classification, the KCCQ and the 6MWT, in symptomatic patients with CC after the use of Dapagliflozin, an SGTL2i inhibitor, for a 12-week period. In this case of series of patients with Chagas Heart Disease, the use of dapagliflozin was associated with significant improvement in symptoms assessed by the NYHA classification and KCCQ scores, however there was not an improvement in performance on the 6MWT.